The cost of headache disorders in Europe: the Eurolight project

Background and purpose: Headache disorders are very common, but their monetary costs in Europe are unknown. We performed the first comprehensive estimation of how economic resources are lost to headache in Europe. Methods: From November 2008 to August 2009, a cross-sectional survey was conducted in eight countries representing 55% of the adult EU population. Participation rates varied between 11% and 59%. In total, 8412 questionnaires contributed to this analysis. Using bottom-up methodology, we estimated direct (medications, outpatient health care, hospitalization and investigations) and indirect (work absenteeism and reduced productivity at work) annual per-person costs. Prevalence data, simultaneously collected and, for migraine, also derived from a systematic review, were used to impute national costs. Results: Mean per-person annual costs were (sic)1222 for migraine (95% CI 1055-1389; indirect costs 93%), (sic)303 for tension-type headache (TTH, 95% CI 230-376; indirect costs 92%), (sic)3561 for medication-overuse headache (MOH, 95% CI 2487-4635; indirect costs 92%), and (sic)253 for other headaches (95% CI 99-407; indirect costs 82%). In the EU, the total annual cost of headache amongst adults aged 18-65 years was calculated, according to our prevalence estimates, at (sic)173 billion, apportioned to migraine ((sic)111 billion; 64%), TTH ((sic)21 billion; 12%), MOH ((sic)37 billion; 21%) and other headaches ((sic)3 billion; 2%). Using the 15% systematic review prevalence of migraine, calculated costs were somewhat lower (migraine (sic)50 billion, all headache (sic)112 billion annually). Conclusions: Headache disorders are prominent health-related drivers of immense economic losses for the EU. This has immediate implications for healthcare policy. Health care for headache can be both improved and cost saving.